간섬유증 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Hepatic Fibrosis Biomarkers Market Size, Share & Trends Analysis Report By Product (Blood-based Kits, Saliva-based Kits), By Technology (Immunofiltration Assays, Lateral Flow Assays), By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,521,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,953,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,818,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

간섬유증 바이오마커 시장 요약

세계 간섬유증 바이오마커 시장 규모는 2024년에 4억 2,351만 달러로 추정되며, 2033년에는 22억 9,173만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 CAGR 20.01%로 성장할 것으로 예상됩니다.

비만, 좌식 생활습관, 대사증후군의 결과로 NASH의 유병률이 증가함에 따라 간섬유화 바이오마커에 대한 관심이 높아지고 있습니다.

National Institutes of Diabetes and Digestive and Kidney Diseases에 발표된 연구에 따르면, NAFLD는 제2형 당뇨병 환자의 3분의 1에서 3분의 2가 앓고 있는 것으로 나타났습니다. 또한, 고도비만인 사람의 90% 이상, 과체중인 사람의 최대 75%가 NAFLD라는 연구 결과도 있습니다. NASH에 특화된 간섬유화 바이오마커에 대한 수요를 촉진하는 주요 요인 중 하나는 섬유화 병기 분류의 임상적 중요성입니다. 비침습적 바이오마커는 간 생검에 따른 위험과 한계로 인해 NASH 환자의 간 섬유화 진행을 모니터링하는 데 있어 보다 안전하고 환자 친화적인 접근법을 제공합니다.

최근 추정에 따르면 전 세계 인구의 약 3.3%가 진행성 간섬유증을 앓고 있으며, 진동 제어 일시적 탄성 검사(VCTE)를 통해 측정하면 그 비율은 약 3.5%로 증가합니다. 비알코올성 지방간질환(NAFLD)은 최근 대사기능장애 관련 지방간질환(MASLD)으로 재정의되어 전 세계 인구의 약 25%가 앓고 있으며, 비만과 제2형 당뇨병의 증가로 인해 2016년부터 2019년까지 특정 지역에서는 유병률이 38%까지 증가할 것으로 예측됩니다.

ELF, FIB-4, NAFLD 섬유증 점수, APRI, FibroTest/FibroSure 등의 검사와 IGFBP7/SSc5D/Sema4D와 같은 새로운 멀티마커 패널의 채택으로 조기발견, 정확한 병기분류, 침습적 간생검에 대한 의존도 감소가 가능해졌습니다. 이러한 발전과 함께 간섬유증 바이오마커는 전 세계적으로 확산되고 있는 간질환의 확산을 막기 위한 핵심 도구로 자리매김하고 있습니다.

간 섬유화의 동역학은 NASH와 같은 비침습적 간질환의 바이오마커가 특히 표적으로 삼을 수 있으며, 환자의 질병 진행을 평가할 수 있는 새로운 도구가 될 수 있습니다. 이러한 간질환 지표는 환자의 위험도 분류 및 고위험군 환자를 대상으로 한 임상시험의 예후 집중에 적용될 수 있어 성공 가능성이 높아집니다. 이러한 혈중 바이오마커는 간 섬유화의 동태를 정확하게 보여주는 지표이기도 하며, 치료의 성공 여부를 가늠할 수 있는 지표로 활용될 수 있습니다. Nordic Bioscience NASH 전문가들은 바이오마커 PRO-C3 NASH를 포함한 간섬유화 바이오마커의 정확한 패널을 검사하여 질병의 경과를 파악할 수 있습니다.

목차

제1장 간섬유증 바이오마커 시장 : 조사 방법과 범위

제2장 간섬유증 바이오마커 시장 : 주요 요약

• 시장 현황
• 제품과 테크놀러지 현황
• 최종 용도 현황
• 경쟁 구도 현황

제3장 간섬유증 바이오마커 시장 변수, 동향, 범위

• 시장 세분화와 범위
• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
• 시장 성장 촉진요인 분석
• 시장 성장 억제요인 분석
• Porter's Five Forces 분석
• PESTLE 분석
• 파이프라인 분석

제4장 간섬유증 바이오마커 시장 : 제품 추정·동향 분석

• 간섬유증 바이오마커 시장 : 제품 변동 분석
• 키트와 시약
• 어세이
• 서비스

제5장 간섬유증 바이오마커 시장 : 기술 추정·동향 분석

• 간섬유증 바이오마커 시장 : 기술 변동 분석
• 면역측정
• 분자진단
• 단백질체학/대사체학
• 이미지 기반 바이오마커 평가

제6장 간섬유증 바이오마커 시장 : 최종 용도 추정·동향 분석

• 간섬유증 바이오마커 시장 : 최종 용도 변동 분석
• 병원
• 진단 연구소
• 전문 클리닉
• 학술연구기관
• 제약·바이오테크놀러지 기업

제7장 간섬유증 바이오마커 시장 : 지역별 비즈니스 분석

• 지역 시장 현황
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 기업 분류
• 전략 매핑
  • 신제품 발매
  • 파트너십
  • 취득
  • 협업
  • 자금 조달
• 주요 기업의 시장 점유율 분석, 2024년
• 기업 히트맵 분석
• 기업 개요
  • GENFIT
  • Prometheus Laboratories
  • Siemens Healthineers AG
  • BioPredictive
  • Quest Diagnostics
  • AstraZeneca
  • Exalenz Bioscience Ltd(meridian bioscience)
  • Labcorp
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

KSM

영문 목차

영문목차

Hepatic Fibrosis Biomarkers Market Summary

The global hepatic fibrosis biomarkers market size was estimated at USD 423.51 million in 2024 and is projected to reach USD 2,291.73 million by 2033, growing at a CAGR of 20.01% from 2025 to 2033. The rising prevalence of NASH, a consequence of obesity, sedentary lifestyles, and metabolic syndrome, has led to a greater focus on hepatic fibrosis biomarkers.

According to the study published in the National Institutes of Diabetes and Digestive and Kidney Diseases, NAFLD affects one-third to two-thirds of individuals with type 2 diabetes. Studies also indicate that over 90% of individuals with extreme obesity and up to 75% of overweight individuals have NAFLD. One of the key drivers propelling the demand for NASH-specific hepatic fibrosis biomarkers is the clinical significance of fibrosis staging. The risks and limitations associated with liver biopsies and non-invasive biomarkers offer a safer and more patient-friendly approach to monitoring hepatic fibrosis progression in NASH patients.

As of the most recent estimates, approximately 3.3% of the global population is living with advanced hepatic fibrosis, with rates rising to around 3.5% when measured using vibration-controlled transient elastography (VCTE). Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), affects about 25% of the world's population, with prevalence increasing to 38% in certain regions between 2016 and 2019 due to rising obesity and type 2 diabetes rates.

The adoption of tests such as ELF, FIB-4, NAFLD fibrosis score, APRI, and FibroTest/FibroSure, alongside emerging multi-marker panels like IGFBP7/SSc5D/Sema4D, is enabling earlier detection, accurate staging, and reduced reliance on invasive liver biopsies. These advancements, combined with rising screening initiatives, are positioning hepatic fibrosis biomarkers as a central tool in tackling the global liver disease epidemic.

The dynamics of liver fibrosis are specifically targeted by noninvasive biomarkers of liver condition, such as NASH, which offer a novel tool to assess a patient's disease progression. Such indicators for liver illness could be applied to patient risk classification as well as prognostic enrichment of clinical trials aimed at the individuals with the highest risk, improving the likelihood of success. These blood biomarkers are also accurate indicators of the dynamics of liver fibrosis and can be used to gauge the success of a given treatment. Nordic Bioscience NASH specialists can examine a precise panel of liver fibrosis biomarkers, including the biomarker PRO-C3 NASH, which offers insight into the course of the illness.

Global Hepatic Fibrosis Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hepatic fibrosis biomarkers market report based on product, technology, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Kits and Reagents
• Assays
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay
• Molecular Diagnostics
• Proteomics/Metabolomics
• Imaging-based Biomarker Assessment
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Specialty Clinics
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Hepatic Fibrosis Biomarkers Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Sample Product segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Hepatic Fibrosis Biomarkers Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Technology Snapshot
• 2.3. End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Hepatic Fibrosis Biomarkers Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
• 3.5. Market Restraint Analysis
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Hepatic Fibrosis Biomarkers Market: Product Estimates & Trend Analysis

• 4.1. Hepatic Fibrosis Biomarkers Market: Product Movement Analysis
• 4.2. Kits and Reagents
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Assays
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Services
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hepatic Fibrosis Biomarkers Market: Technology Estimates & Trend Analysis

• 5.1. Hepatic Fibrosis Biomarkers Market: Technology Movement Analysis
• 5.2. Immunoassays
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Molecular Diagnostics
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Proteomics/Metabolomics
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Imaging-based Biomarker Assessment
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hepatic Fibrosis Biomarkers Market: End Use Estimates & Trend Analysis

• 6.1. Hepatic Fibrosis Biomarkers Market: End Use Movement Analysis
• 6.2. Hospitals
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Diagnostics Laboratories
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Specialty Clinics
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Pharmaceutical & Biotechnology Companies
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Hepatic Fibrosis Biomarkers Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Hepatic Fibrosis Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. GENFIT
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Prometheus Laboratories
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Siemens Healthineers AG
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. BioPredictive
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Quest Diagnostics
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. AstraZeneca
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Exalenz Bioscience Ltd (meridian bioscience)
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Labcorp
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Pfizer Inc.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bristol-Myers Squibb Company
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료